Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 2/20 | 0.48 |
| ▸ | P2RY6 | Q15077 | 10/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309522 | 0.97 | ENPP1 (0.49) | ENPP1P2RY6P2RY2P2RY4POLA1 | |
| SCHEMBL1433847 | 0.86 | ENPP1 (0.46) | ENPP1P2RY6P2RY2P2RY4 | |
| SCHEMBL20798160 | 0.80 | ENPP1 (0.43) | ENPP1P2RY6P2RY2P2RY4POLA1 | |
| Triphosphate SCHEMBL869856 | 0.77 | ENPP1 (0.51) | ENPP1P2RY6P2RY2P2RY4POLA1 | |
| SCHEMBL3436939 | 0.72 | TYMP (0.45) | POLA1 | |
| SCHEMBL28570790 | 0.71 | TYMP (0.44) | POLA1 | |
| SCHEMBL11666542 | 0.70 | CRBN (0.52) | — | |
| SCHEMBL4816453 | 0.70 | P2RY6 (0.36) | P2RY6P2RY2POLA1 | |
| SCHEMBL1452492 | 0.70 | POLB (0.44) | POLA1 | |
| SCHEMBL3364511 | 0.70 | POLB (0.44) | POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 851 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117757649-A | Yeast strain for preparing yeast cell wall polysaccharide extract and application thereof | 安徽科技学院 | 2024-03-26 | — | — | CN | claimed |
| CN-115433263-A | Defensin derived from human oral actinomycetes, and coding gene and application thereof | 中国科学院动物研究所 | 2022-12-06 | — | — | CN | claimed |
| CN-112961911-B | Quantitative analysis method of 5-hydroxymethylcytosine in DNA | 河北大学 | 2022-11-18 | — | — | CN | claimed |
| CN-112646860-B | DNA methylation targeted enrichment method and application thereof | 中国医学科学院北京协和医院 | 2022-10-11 | — | — | CN | claimed |
| CN-112805295-A | Engineering glycosyltransferases and methods of glycosylation of steviol glycosides | 科德克希思公司 | 2021-05-14 | — | — | CN | claimed |
| US-10407703-B2 | Means and methods for producing Neisseria meningitidis capsular polysaccharides of low dispersity | MEDIZINISCHE HOCHSCHULE HANNOVER (DE) | 2019-09-10 | — | — | US | claimed |
| US-9066866-B2 | Direct cellular energy delivery system | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2015-06-30 | — | — | US | claimed |
| WO-2012166742-A2 | SYSTEMS AND METHODS FOR GENETIC AND BIOLOGICAL ANALYSIS | GENAPSYS, INC. (US) | 2012-12-06 | — | — | WO | claimed |
| WO-2026098481-A1 | COMPOSITION AND USE THEREOF | 南京百斯杰生物工程有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-20260130404-A1 | SWEETNESS AND TASTE IMPROVEMENT OF NON-SUCROSE SWEETENERS WITH D-SUGARS OR L-SUGARS | THE COCA COLA CO (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4159050-B1 | STEVIOL GLYCOSIDE COMPOSITIONS FOR ORAL INGESTION OR USE | CARGILL INC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260123656-A1 | NOVEL COMBINATION OF STEVIOL GLYCOSIDES | MORITA KAGAKU KOGYO (JP) | 2026-05-07 | — | — | US | disclosed |
| EP-4704601-A1 | DAIRY-ALTERNATIVE BEVERAGES WITH IMPROVED TASTE | The Coca-Cola Company (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4704600-A1 | DAIRY BEVERAGES WITH IMPROVED TASTE | The Coca-Cola Company (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20070116833-A1 | High-Potency Sweetener Composition with Calcium and Compositions Sweetened Therewith | THE COCA-COLA COMPANY (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070116834-A1 | Condiments with High-Potency Sweetener | THE COCA-COLA COMPANY (US) | 2007-05-24 | — | — | US | disclosed |
| US-7144858-B2 | Antibacterial compounds and methods for treating Gram positive bacterial infections | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2006-12-05 | — | — | US | disclosed |
| WO-2006020372-A2 | ENZYMATIC MODIFICATION OF GLYCOPEPTIDES | NEOSE TECHNOLOGIES, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20050233971-A1 | Antibacterial compounds and methods for treating gram positive bacterial infections | THE TRUSTEES OF THE UNIVERSITY OF PENNSLYVANIA (US) | 2005-10-20 | — | — | US | disclosed |
| WO-2003101393-A2 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR TREATING GRAM POSITIVE BACTERIAL INFECTIONS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050233971-A1 | Antibacterial compounds and methods for treating gram positive bacterial infections | MAN2A1, FUT6, ALG1 | ENPP1 506/4885P2RY6 663/4885P2RY2 1199/4885 |
| US-10407703-B2 | Means and methods for producing Neisseria meningitidis capsular polysaccharides of low dispersity | ENGASE, NANS, FUT5 | ENPP1 454/4885P2RY6 3095/4885P2RY2 3147/4885 |
| US-20260130404-A1 | SWEETNESS AND TASTE IMPROVEMENT OF NON-SUCROSE SWEETENERS WITH D-SUGARS OR L-SUGARS | TAS2R40, TAS2R13, TAS2R31 | ENPP1 4059/4885P2RY6 515/4885P2RY2 392/4885 |
| US-20260123656-A1 | NOVEL COMBINATION OF STEVIOL GLYCOSIDES | TAS2R42, TAS2R10, TAS2R40 | ENPP1 4011/4885P2RY6 1376/4885P2RY2 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.